A new preclinical study suggests that blocking the protein menin could become a powerful treatment for myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers found that the FDA-approved menin inhibitor revumenib significantly extended survival, prevented bone marrow fibrosis, and restored normal blood cell counts in preclinical models. Unlike previous approaches, menin inhibition targeted the disease at its source by eliminating early cancer-forming cells rather than later-stage cells. Since revumenib is already approved for certain types of leukemia, these findings could accelerate clinical trials to evaluate its potential as a new treatment option for patients with MPNs.
Read more at MedicalXpress